Brain Advance Access published online on May 15, 2009
Brain, doi:10.1093/brain/awp113
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PMP22 expression in dermal nerve myelin from patients with CMT1A
1 Department of Neurology, Wayne State University, Detroit, MI, USA 2 Department of Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA 3 John D. Dingell VA Medical Center, Detroit, MI, USA
Correspondence to:
Jun Li, MD, PhD, Department of Neurology, Wayne State University School of Medicine, 4201 St. Antoine, UHC-8D, Detroit, MI 48201, USA E-mail: junli{at}med.wayne.edu
Charcot-Marie-Tooth disease type 1A (CMT1A) is caused by a 1.4 Mb duplication on chromosome 17p11.2, which contains the peripheral myelin protein-22 (PMP22) gene. Increased levels of PMP22 in compact myelin of peripheral nerves have been demonstrated and presumed to cause the phenotype of CMT1A. The objective of the present study was to determine whether an extra copy of the PMP22 gene in CMT1A disrupts the normally coordinated expression of PMP22 protein in peripheral nerve myelin and to evaluate PMP22 over-expression in patients with CMT1A and determine whether levels of PMP22 are molecular markers of disease severity. PMP22 expression was measured by taking skin biopsies from patients with CMT1A (n = 20) and both healthy controls (n = 7) and patients with Hereditary Neuropathy with liability to Pressure Palsies (HNPP) (n = 6), in which patients have only a single copy of PMP22. Immunological electron microscopy was performed on the skin biopsies to quantify PMP22 expression in compact myelin. Similar biopsies were analysed by real time PCR to measure PMP22 mRNA levels. Results were also correlated with impairment in CMT1A, as measured by the validated CMT Neuropathy Score. Most, but not all patients with CMT1A, had elevated PMP22 levels in myelin compared with the controls. The levels of PMP22 in CMT1A were highly variable, but not in HNPP or the controls. However, there was no correlation between neurological disabilities and the level of over-expression of PMP22 protein or mRNA in patients with CMT1A. The extra copy of PMP22 in CMT1A results in disruption of the tightly regulated expression of PMP22. Thus, variability of PMP22 levels, rather than absolute level of PMP22, may play an important role in the pathogenesis of CMT1A.
Key Words: PMP22; CMT1A; CMTNS; HNPP; Schwann cell; myelin; Charcot-Marie-Tooth disease
Abbreviations: CMT1A, Charcot-Marie-Tooth disease type 1A; CMTNS, CMT Neuropathy Score; HNPP, Hereditary Neuropathy with liability to Pressure Palsies; MBP, myelin basic protein; PMP22, peripheral myelin protein 22
Received January 20, 2009. Revised March 3, 2009. Accepted March 26, 2009.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Saporta, I. Katona, R. A. Lewis, S. Masse, M. E. Shy, and J. Li Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A Brain, November 18, 2009; (2009) awp274v1. [Abstract] [Full Text] [PDF]
|
|